Trending NewsTrending NewsNASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis $2.72 +0.28 (+11.27%) As of 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Taysha Gene Therapies Stock (NASDAQ:TSHA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Taysha Gene Therapies alerts:Sign Up Key Stats Today's Range$2.66▼$2.9550-Day Range$1.13▼$2.9352-Week Range$1.05▼$4.32Volume15.63 million shsAverage Volume2.96 million shsMarket Capitalization$582.81 millionP/E Ratio4.31Dividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.Read More… Taysha Gene Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreTSHA MarketRank™: Taysha Gene Therapies scored higher than 67% of companies evaluated by MarketBeat, and ranked 338th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Taysha Gene Therapies' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is 4.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.30.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is 4.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.10.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 6.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Taysha Gene Therapies' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.16% of the float of Taysha Gene Therapies has been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 0.69%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.16% of the float of Taysha Gene Therapies has been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 0.69%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.85 News SentimentTaysha Gene Therapies has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.Search Interest10 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows5 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Stock News HeadlinesStocks to Watch: Nvidia, HP, Taysha Gene TherapiesMay 29 at 11:27 AM | marketwatch.comTaysha Shares Jump 19% Following Favorable Trial Design and FDA Feedback for Rett Syndrome TherapyMay 29 at 11:27 AM | msn.comJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.May 29, 2025 | Premier Gold Co (Ad)Taysha Gene Therapies, Inc. (TSHA)’s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+May 29 at 12:57 AM | insidermonkey.comTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsMay 28 at 10:40 PM | globenewswire.comTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMay 28 at 4:02 PM | globenewswire.comTaysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102May 28 at 4:01 PM | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.57 Consensus PT from BrokeragesMay 28 at 2:39 AM | americanbankingnews.comSee More Headlines TSHA Stock Analysis - Frequently Asked Questions How have TSHA shares performed this year? Taysha Gene Therapies' stock was trading at $1.73 at the start of the year. Since then, TSHA shares have increased by 57.5% and is now trading at $2.7250. View the best growth stocks for 2025 here. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its earnings results on Thursday, May, 15th. The company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). The firm had revenue of $2.30 million for the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative trailing twelve-month return on equity of 106.36%. Read the conference call transcript. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Taysha Gene Therapies' top institutional shareholders include Octagon Capital Advisors LP (5.22%), Siren L.L.C. (3.18%), Siren L.L.C. (3.18%) and Granahan Investment Management LLC (0.80%). Insiders that own company stock include RA Session II, Sean P Nolan, Paul B Manning, Suyash Prasad, Kamran Alam and Sukumar Nagendran. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Taysha Gene Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS). Company Calendar Last Earnings5/15/2025Today5/29/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSHA CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees180Year Founded2020Price Target and Rating Average Stock Price Target$6.57 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+169.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E Ratio3.87 Forward P/E RatioN/A P/E GrowthN/ANet Income-$111.57 million Net Margins-229.67% Pretax Margin-229.67% Return on Equity-106.36% Return on Assets-49.16% Debt Debt-to-Equity Ratio0.48 Current Ratio5.51 Quick Ratio5.51 Sales & Book Value Annual Sales$7.22 million Price / Sales72.50 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book6.10Miscellaneous Outstanding Shares214,662,000Free Float199,410,000Market Cap$523.78 million OptionableOptionable Beta0.90 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:TSHA) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.